Dr Tanveer Tabish
The primary focus of his current research is developing a theranostic approach for the diagnosis and treatment of cancer by combining light and functionalised nanoparticles. The motif is to address the unmet clinical need of immediate and effective non-surgical cancer detection and diagnosis with high specificity and sensitivity in a single effective non-surgical procedure that aim to mimic human response to light and nanoparticles in-vitro and in-vivo. Such a solution does not currently exist, leading to delays in diagnosis, unnecessary mortality, and ineffective treatments, unnecessary treatments with associated risks and significant financial burden to the NHS. He is currently working with the internationally-leading team of multidisciplinary UK-based scientists from University of Exeter, University of Cambridge and University College London. His current research focuses on three major transitions in nanotheranostics: a) development of defined in-vitro and in-vivo model systems, b) nanoparticle/ligand selection and characterisation, and c) the characterisation of nanoparticle targeting. He is exploring novel light-triggered approaches that could play a critical role in each transition, addressing specific questions theoretically, and by chemical and biochemical experiments.
Figure: Schematic illustration of the potential mechanisms by which reactive oxygen species (ROS) are associated with the cellular toxicity of graphene.
From: Tabish, T. A., Zhang, S., & Winyard, P. G. (2018). Developing the next generation of graphene-based platforms for cancer therapeutics: The potential role of reactive oxygen species. Redox biology. 15, 34-40